Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Afatinib in resectable HNSCC
NCT05517330Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Started Sep 2022; status: completed.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05517330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517330.